Literature DB >> 15577440

Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL.

Gregory S Merrick1, Wayne M Butler, Kent E Wallner, Robert W Galbreath, Edward Adamovich.   

Abstract

The objective of this study was to determine the effect of biopsy Gleason score 8 and 9 histology on biochemical outcome following a permanent prostate brachytherapy approach that includes multiple periprostatic seeds and supplemental external beam radiation. Forty-six consecutive T1c-T2b (1997 AJCC) patients with Gleason score 8 and 9 prostate cancer who were either hormone naive (33 patients) or received cytoreductive (< or =6 months) hormonal therapy (13 patients) underwent brachytherapy from June 1995 to November 2000. The median patient age was 69.7 years, with a median pretreatment prostate-specific antigen (PSA) of 7.7 ng/mL. The median follow-up was 58 months (range 27-93 months). Forty-five of the patients were implanted with Pd-103 and 44 received supplemental external beam radiation therapy (45 Gy). Biochemical success was defined by either a PSA < or = 0.4 ng/mL after a nadir or by the ASTRO consensus definition. The actuarial 7-year biochemical disease-free survival was 84.8% using either a PSA < or = 0.4 ng/mL or the ASTRO consensus definition. The median postimplant PSA was less than 0.1 ng/mL for both the hormone naive and hormonally manipulated patients. The utilization of hormonal therapy for 6 months or less duration resulted in a statistically nonsignificant improvement in biochemical outcome (92.3% versus 81.8%, P = 0.393). When stratified by pretreatment PSA, 87.9% of patients with a pretreatment PSA < or = 10 ng/mL and 76.9% with a pretreatment PSA > 10 ng/mL (P = 0.377) remained biochemically free of disease. In multivariate analysis, none of the clinical, treatment, or dosimetric parameters predicted for outcome. Following a permanent prostate brachytherapy approach that used multiple periprostatic seeds, the majority of patients with clinically organ-confined Gleason score 8 and 9 prostate cancer remain biochemically free of disease with identical outcomes for both biochemical definitions of success.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577440     DOI: 10.1097/01.coc.0000135927.83639.5e

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.

Authors:  Michael Dattoli; Kent Wallner; Lawrence True; David Bostwick; Jennifer Cash; Richard Sorace
Journal:  J Oncol       Date:  2010-08-18       Impact factor: 4.375

2.  An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol.

Authors:  Manoop S Bhutani; Jason B Klapman; Richard Tuli; Ghassan El-Haddad; Sarah Hoffe; Franklin C L Wong; Beth Chasen; David R Fogelman; Simon K Lo; Nicholas N Nissen; Andrew E Hendifar; Gauri Varadhachary; Matthew H G Katz; William D Erwin; Eugene J Koay; Eric P Tamm; Ben S Singh; Rutika Mehta; Robert A Wolff; Ashish Soman; Irina M Cazacu; Joseph M Herman
Journal:  Endosc Ultrasound       Date:  2020 Jan-Feb       Impact factor: 5.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.